83
play

!"#$%&'()*+", ( 83"#$&'()*+", ( - PowerPoint PPT Presentation

Apr 16, 2023 •408 likes •509 views

!"#$%&'()*+", ( 83"#$&'()*+", ( -./"0"%1(230$,",(.%(13"(,$#"(,4%1$'&'(2*,.&*%('$%(,"05"( !"#$%&'()*+#,( 9*0( -"#$%&'()#+%&*.,

  1. !"#$%&'()*+", ( 83"#$&'()*+", ( -./"0"%1(230$,",(.%(13"(,$#"(,4%1$'&'(2*,.&*%('$%(,"05"( • !"#$%&'()*+#,( 9*0( -"#$%&'()#+%&*., :(0"20","%1(13"(0*+"(13$1($( .%(6./"0"%1(,"#$%&'(0*+",7(( %*;%(230$,"(2+$4,(<.13(0",2"'1(1*($%($'&*%(*0(,1$1"=(;,;$++4( ">20",,"6(?4($(5"0?7(( !"#$%&'"()%*#)%+,$-"+%+,*#%*#)%#.//)'0%% 1#)%#.//)'%&'"()%*#)%+,$-"+0% • 83"#$&'(0*+",($0"(0"+$1"6(1*(@3$0+",(A.++#*0"B,(13"*04(*C('$,"( D0$##$0,($%6('$,"(0*+",7( 1#)%+,$-"+%&'"()0%% 2"3)'%4/)55)-0%% • E(0"+$&5"+4(,#$++(,"1(*C(13"#$&'(0*+",($0"('*##*%+4(;,"6=( $+13*;D3(13"0"(.,(%*(,.%D+"(6"F%.&5"(,"17(( 653,4%4/)55)-%2"3)'0%% • G"4(H6"$I($?,10$'1($<$4(C0*#(,4%1$>(1*(0"20","%1(13"('*%'"21;$+( 7%.*)%*#)%48.9#):%+,*#%.%;"'(0%% 0*+"(13$1($(230$,"(2+$4,(<.13(0",2"'1(1*($%($'&*%(*0(,1$1"7(( 7%.*)%*#)%48.9#):%+,*#%.%;',)$-0%% 7%.*)%*#)%48.9#):%+,*#%*"/.*"%4.<=)0%% >,?)')$*%4@$*.=A=%').5,B.A"$4%";%*#)%4./)%4)$*)$=)%4#"<5-%&)% 7%.*)%*#)%48.9#):%+,*#%95))0% ')8')4)$*)-%+,*#%*#)%4./)%4)*%";%4)/.$A=%'"5)4C% @*##*%(83"#$&'()*+", ( 83"(ED"%1()*+" ( • ED"%1( • E%( %/#.- (.,(0",2*%,.?+"(C*0($%($'&*%7(NO"%(913*;D3(%*1($+<$4,:( 13.,(.#2+.",(.%1"%&*%$+.147( • 83"#"( • 83"($D"%1(.,(;,;$++4(EPHQE8J7(A*0'",(*C(%$1;0"(9"7D7=( *"'$.-" :(#$4( • H%,10;#"%1( ?"(2"0#.,,.?+"($D"%1,(.C(13"0"(.,(%*( '%0,#( 0*+"7(( • )"'.2."%1( !"#$%&'"()%*#)%+,$-"+0% • J>2"0."%'"0( !"#$%,$*)$A"$.55@%&'"()%*#)%+,$-"+0% • K"%"F'.$04( % 1#)%#.//)'%&'"()%*#)%+,$-"+0% • @$;,"( 1#)%#.//)'%,$*)$A"$.55@%&'"()%*#)%+,$-"+0%%DEF%% • L*'$&*%( • M$13( • E( '*1%/#.-( .,($%*13"0("%&14(13$1($+,*(2"0C*0#"6(13"($'&*%7( ((((( !"#$%8.,$*)-%*#)%+.55%+,*#%G.'@0% ( (

  2. 83"(83"#"()*+" ( 83"(H%,10;#"%1()*+" ( • 83"( -"#$# (9*0( 2%&#.- :(.,(13"(*?R"'1S'*%'"21(?".%D($/"'1"6(*0( E%( 3.,-)0$#.- (0"20","%1,($(1**+=(#$1"0.$+=(*0(C*0'"(13$1(.,(;,"6(1*( $'1"6(;2*%7( 2"0C*0#($%($'&*%7( • 83"(13"#"(.,(;,;$++4(13"($%,<"0(1*(13"(T;",&*%I(( ( ((((( E%(.%,10;#"%1(6*",(%*1(3$5"(1*(?"($(234,.'$+(*?R"'17(H1('$%(?"( (UV3$1(<$,(5"0?W"6XY( $%413.%D(;,"6(1*($''*#2+.,3($%($'&*%7(( 2"3)'%4/)55)-0% 1#)%#.//)'%&'"()%*#)%+,$-"+0%% !"#$%4/)55)-%2"3)'0% 7%.*)%48.9#):%+,*#%.%;"'(0%% !"#$%9.3)%2"3)'%.%&.*#0%% 7%4.+%653,4%+,*#%&,$"=<5.'40%% • E( '*1-"#$# (.,($%*13"0(*?R"'1S'*%'"21(13$1(.,($/"'1"6(*0($'1"6( I)%8.,-%;"'%*#)%')8.,'%<4,$9%#,4%=')-,*%=.'-0% ;2*% 0% I)%<4)-%.%*)5)4="8)%*"%4))%653,40%% % % %!"#$%+.4#)-%2"3)'%.5"$9%+,*#%H$""8@0% !"#$%&'"()%*#)%-""'%-"+$%+,*#%#,4%+),9#*0%% )"'.2."%1=(M*,,",,*0=(K"%"F'.$04 ( 83"(J>2"0."%'"0($%6(@$;,"()*+", ( • 83"( )#'323#.- (0*+"(.,($,,.D%"6(1*($%("%&14(13$1(0"'".5",(,*#"13.%D7( • !*#"(5"0?,(">20",,(.%1"0%$+(?"+."C,=("#*&*%,=(*0(,1$1",7( 83"( #72#)3#.'#) (0*+"(0"20","%1,($%("%&14(<3*(.,( – !"#$%9.3)%.%&,'*#-.@%8')4)$*%*"%G.'@0% ">2"0."%'.%D(,*#"13.%D7( – !"#$%9.3)%G.'@%.%&,'*#-.@%8')4)$*0% – G.'@%&)5,)3)4%*#.*%653,4%,4%4A55%.5,3)0% • 83"( 2*,,#,,*) (0*+"(0"20","%1,(13"(*0.D.%$+(2*,,",,*0(<3"%(13"0"(.,( $('3$%D"(*C(2*,,",,.*%7( – 1#)%&"@%;).'4%48,-)'40% – !"#$%*#')+%.%&.55%*"%G.'@0% • E( '%0,# (0*+"(.,(,*#"&#",(;,"6(C*0("5"%1,(*0(,.1;$&*%,( 13$1(20*6;'"($%("/"'17( • 83"( 4#.#5'3%)6 (0*+"(.,($,,.D%"6(1*($%("%&14(13$1(?"%"F1,(C0*#($%( $'&*%(9<.13*;1(0"'".5.%D($%413.%D:7(( – 1#)%)="$"/,=%')=)44,"$%5)-%*"%/.$@%="'8"'.*)%5.@"?40% – !"#$%4.$9%.%4"$9%;"'%G.'@0% – 1#)%*"'$.-"%-./.9)-%*#"<4.$-4%";%#"/)40% – !"#$%4.$9%G.'@%.%4"$90%

  3. L*'$&*%,=(8.#",=(Q"$,;0"#"%1, ( !"#$%&'(A0$#", ( 8*'%&*. =( !3$# =($%6( 9#%,0)#$#.- (0*+",(#$4(?"(,;?6.5.6"6(.%1*( • E( ,#$%.&'(:)%$#( 9*0( '%,#(:)%$#;( .,($('*%'"21;$+(,10;'1;0"(13$1( ,;?0*+",(0"20","%&%D(6./"0"%1(142",(*C(,1$1"('3$%D",7( 0"20","%1,(13"(,"#$%&'($0D;#"%1,(*C($(<*06(9;,;$++4($(5"0?:7(83"4( *0.D.%$1"6(C0*#(@3$0+",(A.++#*0"B,(13"*04(*C( :)%$#(,#$%.&',<( E8(!1$1"I(( J"4)/,*)%,4%,$%K.5,;"'$,.0%% ! %L1MNOK% • E(C0$#"(0"20","%1,(,"#$%&'([%*<+"6D"($?*;1($%($'&5.14(*0(,1$1"( %%%%%%%%%%%%%%%%%%%%%%7%+"()%<8%.*%P./0%% ! %L1M17G6% 13$1('$21;0",(.1,(#"$%.%D7( % % %%%7%#.3)%QR%-"55.'40%% ! %L1MSLNT6% • H%(,"#$%&',=(20"6.'$1",(1$["( %)/0$#.-, =(<3.'3($0"(%"'",,$04(1*( A)NQS8N(@3$%D"I( 0"20","%1(13"(#"$%.%D(*C($%($'&5.14(*0(,1$1"(6",'0.?"6(.%(1">17(( % %%7%-'"3)%;'"/%T*.#%*"%K.5,;"'$,.0% ! %U2OGMNOK%DO',9,$VH"<'=)F% 983"4($0"(,.#.+$0(1*( '*$2+#$#.-, (.%(,4%1$>7:( %% % % % % % % % % % %%%%%%%%%%%1OMNOK%D>)4A$.A"$F% %% %1#)%8.'*@%4*.'*4%.*%W8/%.$-%)$-4%.*%/,-$,9#*0% ! %U2OGM17G6% J>$#2+",I( .9)$*4Y%*#)/)4Y%')=,8,)$*4% % % % % % % % % % % % % % % %%%1OM17G6% •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`EPHQE8Ja(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( ( (((((((((((((83"#"(_(6.0"'1(*?R"'1((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( ( ( (((((((((((((83"#"(_(6.0"'1(*?R"'1(`MZb!NKca(((((((((((((((((((((((((((((((((((((((((((((((((((((( ( ((((((((((((()"'.2."%1(_(.%6.0"'1(*?R"'1 ( ((((((((((((()"'.2."%1(_(.%6.0"'1(*?R"'1(`EPHQE8Ja ( !"#$%9.3)%G.'@%.%&""(0% !"#$%9.3)%G.'@%.%&""(0% ( ( ]E^J(((((((((((((((((((((((((((((((((((( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ]E^J(((((((((((((((((((((((((((((((((((( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ((((((ED"%1(_( !"#$% ((((((ED"%1(_( !"#$% ((((((83"#"(_( .%&""(% ((((((83"#"(_( .%&""(% (((((()"'.2."%1(_( G.'@ ! (((((()"'.2."%1(_( G.'@ !

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

Have Gods Ear So What is going on in vv. 22-33? Abraham is exploring Gods nature by

Have Gods Ear So What is going on in vv. 22-33? Abraham is exploring Gods nature by

Have Gods Ear So What is going on in vv. 22-33? Abraham is exploring Gods nature by probing His mind! In particular, he wants to know how God justice works What is different about the communication pattern in v. 23? Abraham INITIA

430 views • 13 slides
for some days, and get used to it, the gain will be clearly seen ; we will understand when

for some days, and get used to it, the gain will be clearly seen ; we will understand when

Commentary on the Our Father (Slides 42-100) Slide 42-43 Our Father : Christ as Master and Guide in Prayer Our Father Who Art In Heavenhow You do show Yourself to be the Father of such a Son; and how Your Son does show Himself to be the Son of

395 views • 13 slides
SYNTAX Matt Post IntroHLT class 10 September 2020 and stupor his the Fred with pain from ease

SYNTAX Matt Post IntroHLT class 10 September 2020 and stupor his the Fred with pain from ease

SYNTAX Matt Post IntroHLT class 10 September 2020 and stupor his the Fred with pain from ease couldnt would a set he cigarette out the that for in wife Jones was during caring a often drugs house but screaming the crying at for didnt

1.79k views • 120 slides
Neatening sketched strokes using piecewise French Curves James McCrae, Karan Singh French Curves

Neatening sketched strokes using piecewise French Curves James McCrae, Karan Singh French Curves

Neatening sketched strokes using piecewise French Curves James McCrae, Karan Singh French Curves Physical tools, used to model curves French Curves Smoothly connect pre-determined curve points French Curves French Curves Digital French

845 views • 42 slides
1/30/2017 The GospelFor Jewish People First! Romans 1:1-2 &amp; 16, NIV Paul, a servant of

1/30/2017 The GospelFor Jewish People First! Romans 1:1-2 &amp; 16, NIV Paul, a servant of

1/30/2017 The GospelFor Jewish People First! Romans 1:1-2 &amp; 16, NIV Paul, a servant of Christ Jesus, called to be an apostle and set apart for the Gospel of Godthe gospel he promised beforehand through his prophets in the Holy

157 views • 4 slides
The syntax-semantics interface of PP resultatives in Italian and English Rainer Osswald 1 &amp;

The syntax-semantics interface of PP resultatives in Italian and English Rainer Osswald 1 &amp;

Universidad de La Rioja International Symposium on Verbs, Clauses and Constructions Logroo, 22. 24. 10. 2014 The syntax-semantics interface of PP resultatives in Italian and English Rainer Osswald 1 &amp; Anna Riccio 2 1

548 views • 25 slides
The Remnant And What It Says About Second Temple Judaism Introduction In reference

The Remnant And What It Says About Second Temple Judaism Introduction In reference

The Remnant And What It Says About Second Temple Judaism Introduction In reference to NPP, Richard B. Gaffin, Jr. made the following observations: ...there remained in Pauls day a faithful remnant (e.g., Rom. 11:5; cf. Luke

1.13k views • 68 slides
Lay Summaries How to make them fit-for-purpose Dr DK Theo Raynor Professor of Pharmacy

Lay Summaries How to make them fit-for-purpose Dr DK Theo Raynor Professor of Pharmacy

Risk Management Plan Lay Summaries How to make them fit-for-purpose Dr DK Theo Raynor Professor of Pharmacy Practice University of Leeds, UK and European Medical Academic Advisor, Luto Research Information and Communications Conference

807 views • 36 slides
Prioritising People Prioritising Our Customers... 1 PC15 Lead Communication Pipe Replacement

Prioritising People Prioritising Our Customers... 1 PC15 Lead Communication Pipe Replacement

Prioritising People Prioritising Our Customers... 1 PC15 Lead Communication Pipe Replacement Programme David Emmett DG3 Compliance &amp; WMMWF Project Manager Prioritising People Prioritising Our Customers... 2 Why the need to reduce

373 views • 21 slides
Jennie Connor Department of Preven1ve and Social Medicine

Jennie Connor Department of Preven1ve and Social Medicine

Jennie Connor Department of Preven1ve and Social Medicine University of Otago, Dunedin Global Burden of Disease 2010 High blood pressure Tobacco smoking, including

437 views • 15 slides
Healthcare Leadership Council: Care Transitions in Post Ac te Care Care Transitions in Post Acute

Healthcare Leadership Council: Care Transitions in Post Ac te Care Care Transitions in Post Acute

Healthcare Leadership Council: Care Transitions in Post Ac te Care Care Transitions in Post Acute Care John Perticone Golden Living 3/9/2016 Golden Living Profile Golden Living Centers and Aegis Therapies AseraCare Communities

153 views • 13 slides
Comprendre la thrombose grce lOCT Nicolas Amabile, MD, PhD Service de Cardiologie,

Comprendre la thrombose grce lOCT Nicolas Amabile, MD, PhD Service de Cardiologie,

OCT : toute la lumire sur langioplastie Comprendre la thrombose grce lOCT Nicolas Amabile, MD, PhD Service de Cardiologie, Institut Mutualiste Montsouris, Paris DCLARATION DE LIENS D'INTRT AVEC LA PRSENTATION Intervenant :

686 views • 24 slides
functional assessment of stents Prof. T. Adriaenssens, MD, PhD University Hospitals Leuven,

functional assessment of stents Prof. T. Adriaenssens, MD, PhD University Hospitals Leuven,

Your logos here Relation between OCT imaging &amp; functional assessment of stents Prof. T. Adriaenssens, MD, PhD University Hospitals Leuven, Belgium OCT &amp; FFR post stent implantation: Should they relate? OCT : detailed cross

1.1k views • 25 slides
IHPA and Activity Based Funding Dr Tony Sherbon Chief Executive Officer National Health Reform

IHPA and Activity Based Funding Dr Tony Sherbon Chief Executive Officer National Health Reform

IHPA and Activity Based Funding Dr Tony Sherbon Chief Executive Officer National Health Reform Agreement Signed by all First Ministers in August 2011 Activity based funding has been a requirement of Commonwealth funding for

546 views • 25 slides
RECOVERY AFTER SUBARACHNOID HEMORRHAGE Lisa T Hannegan, MS CNS, ACNP I HAVE NO FINANCIAL

RECOVERY AFTER SUBARACHNOID HEMORRHAGE Lisa T Hannegan, MS CNS, ACNP I HAVE NO FINANCIAL

9/7/2013 RECOVERY AFTER SUBARACHNOID HEMORRHAGE Lisa T Hannegan, MS CNS, ACNP I HAVE NO FINANCIAL Department of Neurological Surgery University of California, San Francisco DISCLOSURES TO REPORT OVERVIEW OF RECOVERY AFTER SUBARACHNOID

530 views • 19 slides
Unexpectedly acceptable Philip Miller, Universit Paris Diderot,

Unexpectedly acceptable Philip Miller, Universit Paris Diderot,

Unexpectedly acceptable Philip Miller, Universit Paris Diderot, philip.miller@univ-paris-diderot.fr Structure and Evidence in Linguistics Workshop in Honor of Ivan A. Sag Cordura Hall, Stanford University April 28-30, 2013 1

365 views • 22 slides
Microtesting How we set fire to the testing pyramid while maintaining confidence Rob Moore

Microtesting How we set fire to the testing pyramid while maintaining confidence Rob Moore

Microtesting How we set fire to the testing pyramid while maintaining confidence Rob Moore Matt Davies Principal Consultant, Readify Lead Consultant, Readify Why microtesting? Because we wanted to be part of the cool club Because we wanted

591 views • 38 slides
Work Group Considerations and Next Steps Kathleen Dooling, MD MPH June 24, 2020 For more

Work Group Considerations and Next Steps Kathleen Dooling, MD MPH June 24, 2020 For more

ACIP COVID-19 Vaccines Work Group Work Group Considerations and Next Steps Kathleen Dooling, MD MPH June 24, 2020 For more information: www.cdc.gov/COVID19 Work Group Considerations: Objectives of the COVID-19 Vaccine Program Ensure safety

329 views • 13 slides
Daratumumab Michele Cavo Sergnoli Institute of Hematology Bologna University School of

Daratumumab Michele Cavo Sergnoli Institute of Hematology Bologna University School of

Three recent impressive stories: Daratumumab Michele Cavo Sergnoli Institute of Hematology Bologna University School of Medicine Bologna, Italy New Drugs in Hematology, October 1-3, 2018, Bologna, Italy Myeloma Drug Development 2

1.54k views • 45 slides
Radiotherapy Considerations in Extremity Sarcoma Peter Chung Department of Radiation Oncology

Radiotherapy Considerations in Extremity Sarcoma Peter Chung Department of Radiation Oncology

Radiotherapy Considerations in Extremity Sarcoma Peter Chung Department of Radiation Oncology Princess Margaret Hospital University of Toronto Role of RT in STS Role of RT in STS Local tumour eradication while allowing successful limb

416 views • 23 slides
Comprehensive Care of Delirious Patients Vanja Douglas, MD Sara &amp; Evan Williams Foundation

Comprehensive Care of Delirious Patients Vanja Douglas, MD Sara &amp; Evan Williams Foundation

10/14/2016 Comprehensive Care of Delirious Patients Vanja Douglas, MD Sara &amp; Evan Williams Foundation Endowed Neurohospitalist Chair Associate Professor of Clinical Neurology UCSF Department of Neurology Neurohospitalist Program Disclosures

607 views • 31 slides
A New Practical Intracerebral Hematoma Volume Calculation Method and Comparison to simple ABC/2

A New Practical Intracerebral Hematoma Volume Calculation Method and Comparison to simple ABC/2

A New Practical Intracerebral Hematoma Volume Calculation Method and Comparison to simple ABC/2 F.Cuce , G. Tulum, O. Dandin, T. Ergin, O. Karadas, O. Osman Gulhane Education and Training Hospital, Department of Radiology, Ankara, Turkey

526 views • 20 slides
UC UC SF SF Vascular Trauma @ SFGH: Practical Lessons Learned Shant M. Vartanian, MD

UC UC SF SF Vascular Trauma @ SFGH: Practical Lessons Learned Shant M. Vartanian, MD

UC UC SF SF Vascular Trauma @ SFGH: Practical Lessons Learned Shant M. Vartanian, MD Assistant Professor of Surgery Division of Vascular and Endovascular Surgery Priscilla and Mark Zuckerberg San Francisco General Hospital and Trauma Center

552 views • 13 slides
CLL - ibrutinib Peter Hillmen peter.hillmen@nhs.net St Jamess University Hospital Leeds 10 th

CLL - ibrutinib Peter Hillmen peter.hillmen@nhs.net St Jamess University Hospital Leeds 10 th

CLL - ibrutinib Peter Hillmen peter.hillmen@nhs.net St Jamess University Hospital Leeds 10 th May 2016 Life Cycleof the CLL Cell Peripheral Tissue circulation compartments Stromal CpG DNA VCAM-1 Antigen CLL BCR CXCL13 CLL

596 views • 38 slides

More recommend